In the study, 61.9% of patients were given the highest dose of the drug. Top-line data from the phase III REDEFINE 2 study showed that treatment with CagriSema led to a weight loss of 15.7% after ...

Novo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche ... CagriSema, a follow-up drug to Wegovy. CagriSema is a fixed-dose combination of a long-acting amylin analog, cagrilintide ...

Arvinas suffered a major financial blow after its breast cancer drug, vepdegestrant, failed to deliver broad success in a final-stage trial. The treatment, developed in partnership with Pfizer, did ...

Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in rival Eli Lilly also sold off. Find out more: New trial data showed the ...

China’s 4 per cent increase in retail sales in the first two months of the year beats estimates of 3.8 per cent gain.

This analysis will delve into Amneal’s recent financial performance, market position, and future prospects, providing a comprehensive overview for investors considering the stock. Amneal ...

Image Protect, Inc. develops review and reputation management software and services to individuals and businesses. It offers review marketing software subscription products. The company is based ...

Xan Saks, a respected figure in commercial real estate, has led Beta Agency’s remarkable growth over six years, transforming it into a national powerhouse representing over 500 companies. His ...

Eli Lilly‘s stock fell 4.58% following weak trial results from Novo Nordisk’s obesity drug, shaking investor confidence in the sector. Despite the dip, Eli Lilly remains financially strong, with an ...

Here is how the Barron’s Roundtable members’ picks performed. Find investment ideas for your portfolio with the latest stock picks from Barron’s below. These picks are the product of the ...